Announcements
- Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
- Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
- Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
- Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
- Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
- Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
- Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
More ▼
Key statistics
On Friday, Ovid Therapeutics Inc (1OT:BER) closed at 2.94, 18.55% above the 52 week low of 2.48 set on Mar 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.94 |
---|---|
High | 2.94 |
Low | 2.94 |
Bid | 3.06 |
Offer | 3.10 |
Previous close | 2.92 |
Average volume | 103.10 |
---|---|
Shares outstanding | 70.94m |
Free float | 59.68m |
P/E (TTM) | -- |
Market cap | 233.41m USD |
EPS (TTM) | -0.7174 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 07:09 BST.
More ▼